Shineco Dual-Engine Breakthrough: Subsidiary Dong'ao Health Secures USD 8.7 Million R&D Contract and Enters Comprehensive Collaboration with Singapore Biotech Leader BICC

BEIJING, , 2025 -- Shineco Inc. (NASDAQ: SISI) (“Shineco” or the “Company”), a leading developer of induced pluripotent stem cell (iPSC) technology platforms, today announced two major strategic developments: its subsidiary, Xi’an Dong’ao Health Management Co., Ltd. (“Dong’ao Health”), recently signed a technology services contract valued at USD 8.7 million with Xinke Future Biotechnology (Bazhou) Co., Ltd. for the research and development of “microalgae-derived extracellular vesicles” technology. Meanwhile, a delegation from Singapore's leading biotechnology company, BICC, completed a site visit to Dong’ao Health on September 10. The two parties reached deep consensus on key collaborative directions including the establishment of a joint laboratory and technology exchange and sharing, marking the entry of Shineco’s “technology industrialization + global synergy” strategy in the biocellular field into a substantive implementation phase.

As the core entity executing Shineco’s strategy to develop “new business formats in the biocellular market,” the technology R&D contract signed by Dong’ao Health focuses on cutting-edge research in microalgae-derived extracellular vesicles technology. The service period runs from August 25, 2025, to December 31, 2026, aiming to build a full-chain R&D system from “basic research – process development – product translation.” Specific tasks include functional validation at the basic research stage; breaking through the bottlenecks of hectoliter-scale separation and extraction processes to achieve large-scale production at the industrialization stage; and developing at least two therapeutic products with full-process registration support at the translation and application stage, effectively advancing the technology from the laboratory to the market.

The contract is expected to provide clear growth momentum for Shineco: the total contract value of USD 8.7 million will be paid in phases, with an initial payment of USD 560,000 already received. Subsequent payments are closely linked to R&D milestones, not only ensuring stable revenue recognition but also fostering long-term profit growth points for the Company through the “one-time development, multiple reuses” technological feature. Jennifer Zhan, CEO of Shineco, stated, “This contract confirms our ability to transform cutting-edge technology into scalable revenue. Microalgae-derived extracellular vesicles technology strongly complements the Company’s existing cell therapy business and will serve as a new engine for growth.”

Alongside progress in R&D, Shineco’s international cooperation has also achieved key advancements. Singapore-based biotechnology company BICC sent a high-level delegation to visit Dong’ao Health from September 6 to 10. The delegation members included Mr. Yang Shengnan, Chairman of the Board; Ms. Barbara Tan, CEO; Mr. Jon Lim, CFO; Mr. Chen Yanming, Chief Scientist; and Mr. Chen Laifu, Shareholder, covering core resources in strategy, scientific research, capital, and other key areas.

The delegation conducted on-site inspections of Dong’ao Health’s four core segments—the Health and Wellness Center, Cell R&D Center, under-construction Alzheimer’s Disease Care Town, and partner “Anhe Meige Medical Aesthetic Hospital”—focusing on evaluating the potential for collaboration in technology complementarity and market resource synergy. Ultimately, the two parties agreed to jointly establish a laboratory, create a technology exchange mechanism, integrate BICC’s network of over 3,000 agents in Southeast Asia with Dong’ao Health’s domestic wellness channels, and co-establish stem cell transfusion centers to promote the standardization of clinical services.

The dual advancement of the R&D contract and international collaboration clearly reflects Shineco’s dual-driver strategy of “technology R&D + ecosystem synergy.” Technologically, Dong’ao Health and BICC achieve “complementary application scenarios + synergistic R&D capabilities." From a market perspective, the scalable revenue brought by the USD 8.7 million contract and the international potential of BICC's channels jointly construct a structure of "domestic foundation + international new markets." Financially, contract payments will improve cash flow in the short term, while profitability will be enhanced in the long term through technology reuse and market expansion.

Jennifer Zhan, CEO of Shineco, emphasized, "These two developments demonstrate the effective operation of the Company's complete value transformation chain from 'technology to industry to capital.' Shineco will continue to deepen its technology industrialization layout and promote international cooperation with an open attitude to create sustainable returns for shareholders."

According to the plan, Shineco will regularly disclose the execution progress of the R&D contract and the collaboration with BICC in accordance with NASDAQ disclosure requirements, providing investors with clear references for value assessment.

About Xi'an Dong'ao Health Management Co., Ltd.

Xi'an Dong'ao Health provides GMP-compliant biostorage and clinical cell applications, delivering integrated health management via "Prevention-Intervention-Maintenance" protocols.

About BICC Pte Ltd

Founded in 2024, BICC is an innovative biotechnology holding company that unites a world-class team of scientists and medical experts specializing in stem cell treatments and artificial intelligence. With a strategic presence across Asia—including offices in China, Thailand, and Singapore—BICC leverages its proprietary stem cell technologies, such as patented serum-free media, iPSC-derived therapies, and clinically proven wound-healing applications, alongside personalized cell banking services. This expertise is enhanced by a suite of science-backed wellness offerings, including regenerative treatments, anti-aging supplements, and exosome-based cosmetics, positioning BICC at the cutting edge of integrated health solutions. For more information about BICC, please visit www.BICC.sg.

About Shineco, Inc.

Shineco, Inc. is dedicated to improving quality of life through the development and provision of safe, efficient, and high-quality health and medical products and services. The Company's core business focuses on induced pluripotent stem cell (iPSC) technology platforms and extracellular vesicle-derived products. For more information, please visit www.biosisi.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by words such as "may," "will," "should," "could," "intend," "expect," "plan," "budget," "forecast," "anticipate," "believe," "estimate," "forecast," "potential," "continue," "evaluate" or similar words. Forward-looking statements should not be relied upon as they are neither historical facts nor guarantees of future performance. Rather, they are based solely on our current beliefs, expectations and assumptions about future business, future plans and strategies, forecasts, expected events and trends, economics, and other future conditions. Examples of forward-looking statements include, among other things, our innovation and market position in our products and services, our competitive advantages, and our expectation that the 5-minute cardiac test will be one of the leading products in this field to meet the need for test results immediately upon intake. Please do not rely on any forward-looking statements. Actual results may differ materially from those indicated in historical results or forward-looking statements due to various factors, including, but not limited to, the Company's ability to raise additional capital, its ability to maintain and grow its business, the variability of its results of operations, its ability to maintain and enhance its brand, its ability to develop and introduce new products and services, its ability to obtain all necessary regulatory approvals in the jurisdictions in which it intends to market and sell its products, companies to be acquired, successful integration of technology and assets into its portfolio of products and services, marketing and other business development initiatives, industry competition, general government regulations, economic conditions, impact of the COVID-19 pandemic, reliance on key personnel, attracting, hiring and retaining personnel with the technical skills and experience required to meet customer requirements and protecting its intellectual property. Shineco encourages you to review these and other factors that may affect its future performance in its filings with the Securities and Exchange Commission. The forward-looking statements in this *press release are based only on information currently available to us and are made only as of the date of this press release, and Shineco undertakes no obligation to update any forward-looking statements, except as required by applicable rules and regulations.*

For more information, please contact:

Shineco, Inc.
Email: secretary@shineco.tech
Phone: +86-10-68130220